CYTOGEN, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,360 KRW | -3.74% |
|
-1.51% | -8.58% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Cytogen Inc is a Korea-based company mainly engaged in the provision of liquid biopsy application services. The liquid biopsy application services include biomarker discovery and verification services, as well as liquid biopsy-based precision medical services which is the commercialization of companion diagnostics (CDx) development, among others. The biomarker discovery and verification services include circulating tumor cell (CTC)-based biomarker discovery and validation, gene mutation and transcript expression analysis, and drug testing and analysis services, among others. The liquid biopsy-based precision healthcare services include companion diagnosis, re-selection of therapeutic drugs, examination and treatment effectiveness monitoring, and recurrence prediction services, among others. In addition, the Company develops and sells platforms and kits for liquid biopsy. The Company distributes its products within the domestic market and to overseas markets.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.58% | 209M | |
| -19.64% | 10.82B | |
| +47.91% | 3.25B | |
| -32.87% | 2.11B | |
| -14.15% | 2.08B | |
| -25.41% | 1.48B | |
| +18.78% | 1.02B | |
| -2.62% | 733M | |
| -31.12% | 391M | |
| -43.78% | 383M |
- Stock Market
- Equities
- A217330 Stock
- News Cytogen, Inc.
- Cytogen Raising KRW10 Billion to Finance Operations
